Idorsia Ltd. · SIX:IDIA
Idorsia — Corporate Update (June 2018)
33 slides from Idorsia's corporate update, June 2018
Slide 1: Phase 3 investigation of clazosentan for vasospasm post-aSAH
Phase 3 investigation of clazosentan for vasospasm post- aneurysmal subarachnoid hemorrhage Investor Webcast – June 2018
Slide 2: Forward-looking statements
The following information contains certain “forward-looking statements”, relating to the company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “are expected to”, “will”, “will continue”, “should”, “would be”, “seeks”,
Slide 3: More knowledge – Powered by science
More knowledge – Powered by science Jean-Paul Clozel, MD CEO 3 Phase 3 initiation in vasospasm post-aSAH | June 2018
Slide 4: Our Strategic Priorities
Our Strategic Priorities 1 Deliver at least three products to market 5 key priorities to ensure the company’s success 2 Build a commercial organization over the next 5 years 3 Bring Idorsia to profitability in a sustainable manner 4 Create a pipeline with a sales potential of CHF 5 billion 5 Utilize
Slide 5: Phase 3 investigation of clazosentan for vasospasm post-aSAH
Phase 3 investigation of clazosentan for vasospasm post-aneurysmal subarachnoid hemorrhage Guy Braunstein, MD Head of Global Clinical Development 5 Phase 3 initiation in vasospasm post-aSAH | June 2018
Slide 6: Aneurysmal subarachnoid hemorrhage (aSAH)
Aneurysmal subarachnoid hemorrhage (aSAH) A sudden life-threatening bleeding occurring in the subarachnoid space • aSAH is caused by the rupture of an aneurysm Scalp – a weak, bulging spot on the wall of a cerebral artery Skull • Prevalence: 9 in 100’000 worldwide – Subarachnoid it is an orphan dise
Slide 7: Cerebral vasospasm post-aSAH
Cerebral vasospasm post-aSAH Can occur between 4 and 14 days after aSAH securing Artery spasm • Cerebral vasospasm is a strong contraction of the arteries in the brain surrounding the hemorrhage Blood • Narrowing of the blood vessel limits blood flow decreasing the amount of blood supplied to the br
Slide 8: Clinical manifestations of vasospasm
Clinical manifestations of vasospasm From asymptomatic detected by systematic Long-term consequence of vasospasm angiography to serious neurological symptoms • Necrosis of an area of brain tissue Loss of • Physical deficit consciousness • Social and emotional impact, affecting all Blurred or double
Slide 9: Available therapy for vasospasm
Available therapy for vasospasm Hemodynamic therapy Rescue therapy No pharmacological therapy for • Inducing high blood pressure in • Invasive neurovascular intervention cerebral vasospasm an attempt to force a blood − balloon angioplasty • Except for fasudil in Japan and supply to the brain region
Slide 10: Rationale for clazosentan for cerebral vasospasm
Rationale for clazosentan for cerebral vasospasm Role of endothelin in cerebral vasospasm Clazosentan Cerebral vasospasm is caused by the release of vasoactive ETA selective ERA mediators after a bleed on the brain triggering vessels to contract Patients with cerebral Highly soluble vasospasm show h
Slide 11: Learning from clazosentan program
Learning from clazosentan program Vasospasm ≈ day 4 to 14 Initial SAH Aneurism Asymptomatic Vasospasm- Hospital Delayed, event secured vasospasm related symptoms discharge 3 to 6 month outcome More than 1’800 patients treated with clazosentan providing significant CONSCIOUS experience in vasospasm p
Slide 12: What we have learned through our experience with clazosentan
What we have learned through our experience with clazosentan… Sebastien Roux, MD Medical lead for clazosentan Clazosentan is investigational, in development and not approved or marketed in any country. 12 Phase 3 initiation in vasospasm post-aSAH | June 2018
Slide 13: CONSCIOUS-1: Dose-dependent prevention of vasospasm
Clazosentan Dose-dependent prevention of vasospasm CONSCIOUS-1 Phase 2 study – 80 All patients (per-protocol) angiographic endpoint 70 • Clazosentan 1 to 15 mg/h versus Patients with moderate/severe 60 placebo post-clipping and coiling *p = 0.0027 vasospasm (%) 50 *p = 0.0003 40 *p < 0.0001 30 20 10
Slide 14: CONSCIOUS-2: 5mg/hr dose is not high enough
Clazosentan 5mg/hr dose is not high enough CONSCIOUS-2 Overall incidence of death and vasospasm-related morbidity Phase 3 study – clinical morbidity / mortality endpoint • Patients who received surgical clipping treated with 5mg/hr clazosentan Event rate (%) The Lancet. Neurology, 2011; 10(7):618-62
Slide 15: CONSCIOUS-3: 15mg/hr showed significant effect on morbidity / mortality
Clazosentan 15mg/hr showed significant effect on morbidity / mortality CONSCIOUS-3 Overall incidence of death and vasospasm-related morbidity Phase 3 study – clinical morbidity / mortality endpoint • Patients who received endovascular coiling treated with 5 or 15mg/hr clazosentan Stroke. 2012; 43(6)
Slide 16: CONSCIOUS-3: 15mg/hr showed significant effect on primary endpoint
Clazosentan 15mg/hr showed significant effect on primary endpoint CONSCIOUS-3 Incidence of death and each component Phase 3 study – clinical of vasospasm-related morbidity morbidity / mortality endpoint • Consistent effect at 15 mg/hr on all 25 morbidity events 21 21 20 18 16 Event rate (%) 15 13 15
Slide 17: Japanese study: 10mg/hr showed similar results
Clazosentan 10mg/hr dose showed similar results to CONSCIOUS-3 in Japanese patients Japanese study Overall incidence of death and vasospasm-related morbidity Phase 2 study – exploratory endpoint • Clazosentan significantly reduced vasospasm-related morbidity and mortality events Cerebrovasc Dis 2017
Slide 18: REVERSE: In patients with established vasospasm
Clazosentan In patients with established vasospasm REVERSE Pilot study – angiographic endpoint Key findings: • Clazosentan acts on some large brain arteries but the real benefit is in the Indicates moderate effect on smaller arteries not vasospasm accessible to endo-arterial therapy • Clazosentan ha
Slide 19: Well documented safety profile
Clazosentan Well documented safety profile Side effects of clazosentan Risk mitigation Hypotension Blood pressure control with vasopressors in ICU Lung complications Euvolemia, (pulmonary edema) iv fluid restriction Peripheral edema Euvolemia, iv fluid restriction > 1’800 patients treated Main side
Slide 20: Which patients are at highest risk of vasospasm?
Which patients are at highest risk of vasospasm? Patients with “thick and diffuse” clot • Characterized by large amount of subarachnoid blood on hospital admission cerebral CT scan • Represents approximately 50% of overall aSAH population Normal CT Thick and diffuse SAH Clazosentan is investigationa
Slide 21: Which patients are at highest risk of vasospasm? Event rates
Which patients are at highest risk of vasospasm? CONSCIOUS-2 CONSCIOUS-3 Patients with “thick and diffuse” clot • Data from previous CONSCIOUS program demonstrates the high event Rescue Therapy rates for vasospasm and related ischemic complications DIND New Cerebral Infarcts Death 0% 10% 20% 30% Pro
Slide 22: Clazosentan in high-risk patient population
Clazosentan In high-risk patient population CONSCIOUS-2 CONSCIOUS-3 Clot size impacts the absolute treatment effect (individual morbidity / mortality components) Phase 3 studies – clinical morbidity / mortality endpoint Thick and Diffuse Clots Placebo Clazosentan 5 mg/h Clazosentan 15 mg/h DIND = De
Slide 23: REACT study design incorporates these learnings
REACT study design incorporates these learnings Selection of Selection of Selection of Optimized patient the a high-risk the dose the best measure management patient to demonstrate guidelines to ensure population efficacy patient safety Clazosentan is investigational, in development and not approved
Slide 24: REACT: Objectives
REACT: Objectives Primary objective • To determine the efficacy of clazosentan in preventing clinical deterioration due to delayed cerebral ischemia, in patients with aSAH Secondary objectives • To evaluate the effect of clazosentan on the incidence of all-cause new or worsened cerebral infarction ≥
Slide 25: REACT: Design
REACT: Design 400 patients (200 placebo/200 clazosentan) from 100 trial sites across 15 countries Observation: 14 days post-study drug initiation Placebo Treatment & Observation 24h Safety Screening Follow-up Extended Follow-up Clazosentan 15mg/h Treatment & Observation Aneurysm Hospital Randomizati
Slide 26: REACT: Patient population
REACT: Patient population Target population: elevated risk of developing delayed cerebral ischemia (DCI) High-risk for developing Early vasospasm without cerebral vasospasm Objective to prevent neurological deterioration DCI, subsequent • “thick and diffuse” clot on clinical deterioration, • clazose
Slide 27: REACT: Primary endpoint – highly relevant
REACT: Primary endpoint – highly relevant The occurrence of clinical deterioration due to DCI, from study drug initiation up to 14 days post-study drug initiation • Worsening of 2 points on neurological scales, lasting for at least 2 hours • Entirely or partially due to cerebral vasospasm • Centrall
Slide 28: Secondary endpoints
Secondary endpoints • Occurrence of all-cause new or worsened cerebral infarction ≥ 5 cm3 at Day 16 post-study drug initiation • Long-term clinical outcome assessed by the GOSE at Week 12 post-aSAH, dichotomized into poor (score ≤ 4) and good outcome (score > 4) • Instruments used to assess long-ter
Slide 29: Japanese registration program
Japanese registration program • Two identically designed studies (one in clipped patients, one in coiled patients) evaluating the effect of clazosentan 10 mg/h versus placebo on vasospasm-related morbidity and mortality and all-cause morbidity and mortality − Death, new cerebral infarcts, delayed is
Slide 30: Summary
Summary • Developed as intravenous infusion for prevention and treatment Cerebral vasospasm of cerebral vasospasm in patients who have suffered an aSAH Compound: Clazosentan • Has potential to prevent ischemic complications of cerebral vasoconstriction and to Mechanism of action: decrease the need f
Slide 31: Idorsia Pharmaceuticals Japan
Idorsia Pharmaceuticals Japan Jean-Paul Clozel, MD CEO 31 Phase 3 initiation in vasospasm post-aSAH | June 2018
Slide 32: Why launch our first affiliate in Japan
Why launch our first affiliate in Japan • Many drugs discovered and developed by Idorsia address important clinical needs in Japan, such as: − Fabry Disease − Resistant hypertension − Systematic Lupus Erythematosus • Dr. Satoshi Tanaka Leadership: Built Actelion Japan and developed and launched 5 dr
Slide 33: Physician quote on vasospasm
“It is very frustrating to see our patients survive the initial trauma of the brain hemorrhage and seemingly make a recovery, only for the vasospasm to take hold and cause significant long-term damage.” – Physician 33 Phase 3 initiation in vasospasm post-aSAH | June 2018